This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anterior Pituitary Function in Patients With Hydrocephalus

This study has been terminated.
Eli Lilly and Company
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Identifier:
First received: September 7, 2005
Last updated: March 1, 2010
Last verified: March 2010
Hydrocephalus (secondary or idiopathic) is a condition characterized by dilatation of the lateral and third ventricles, and often associated with increased intracranial pressure (ICP). We hypothesize that either the ventricle dilatation or the increased ICP may cause disturbances in the hypothalamic-pituitary axis, resulting in different degrees of hypopituitarism. The goal of this study is to determine the prevalence of hypopituitarism in adult patients with hydrocephalus.

Condition Intervention
Normal Pressure Hydrocephalus Procedure: Ventriculo-peritonal shunting

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Anterior Pituitary Function in Patients With Hydrocephalus

Resource links provided by NLM:

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • anterior pituitary function

Secondary Outcome Measures:
  • well being

Estimated Enrollment: 30
Study Start Date: September 2005
Estimated Study Completion Date: December 2007
Detailed Description:

The Johns Hopkins Adult Hydrocephalus Program evaluates approximately 250 new patients per year for hydrocephalus and associated disorders, resulting in the new diagnosis of hydrocephalus in about 100 patients annually. After treatment with either shunt surgery or third ventriculostomy, virtually all patients are followed on a regular basis by physicians in the program (Dr. Michael Williams, neurologist, and Dr. Daniele Rigamonti, neurosurgeon, both involved in this project).

These patients represent an ideal cohort to study the effect of hydrocephalus on anterior pituitary function. In addition, as data on intracranial pressure is available for all of them, evaluation of pituitary function would allow us to determine whether the level of intracranial pressure correlates with the likelihood of pituitary failure.

We propose to study 20 subjects of both sexes with NPH, aged 18-80 years over a period of 18 months. They will be recruited by direct advertising among the patients cared for by the Adult Hydrocephalus Program. Patients with hydrocephalus will be studied twice (6-12 months apart) whether or not they undergo shunting.


  1. In addition to the comprehensive neurological history and physical examination, further history will be obtained, with particular attention to sexual function and libido in males and menstrual history in women of fertile age, will be collected.
  2. After overnight fasting, an indwelling catheter will be inserted in a peripheral vein. Blood for baseline hormonal evaluation (8-9 AM) including: serum free T4 (FT4), TSH, cortisol, GH, IGF-1, prolactin, LH, FSH, Estradiol (in females) and total testosterone (in males). Menstruating females will be studied during follicular phase. Serum IGF-1, testosterone, estradiol and gonadotropin levels will be interpreted in accordance with the patients' age.
  3. All subjects will undergo GH stimulation test by combination of GHRH (1 mcg/kg bolus) and arginine (0.5 gm/kg over 30', maximal dose 30 gm). Blood will be dawn at time 30', 60', 90' and 120' after the GHRH bolus injection. The GHRH+arginine test is the most widely used test to determine GH reserve in adults, independently from their age (14). Normal response is a peak serum GH > 9 ng/ml. Both GHRH and arginine are FDA-approved for this purpose, and have no significant side effects (GHRH may cause transient itching and flushing).
  4. An AM cortisol below 5 mcg/dl will be considered diagnostic of adrenal insufficiency. Conversely, a value above 15 mcg/dl will be interpreted as indicating normal adrenal function. For serum cortisol values between 5 and 15 mcg/dl, subjects will be studied on a separate day by low-dose (1 mcg) ACTH stimulation test. Blood for serum cortisol measurement will be obtained at baseline and after 30' from ACTH injection. The low-dose ACTH stimulation test is safe, easy to perform, has high sensitivity for partial secondary adrenal insufficiency, and has been recently used in patient with TBI. Normal response is a serum cortisol at 30' > 18.0 mcg/dl.

Subjects who have shunt surgery will undergo a second study of pituitary function not earlier than 6 months and no later than 1 year from the procedure. We will identify the degree of clinical improvement by documenting change in gait with the Tinetti Gait Assessment Tool, and change in dementia with the Mini-Mental-Status exam. If there is sufficient sample size in the clinically improved and unimproved patients, we will compare between-group results.

Patients who have been on systemic glucocorticoids (GC) for longer than 3 weeks during the previous 12 months will be excluded, as GC may cause suppression of hypothalamic-adrenal axis. In subjects who are on phenytoin, unbound T4 will be measured by equilibrium dialysis, as phenytoin may interfere with direct unbound T4 measurement. Subjects already on L-thyroxine replacement will be excluded.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Diagnosis of idiopathic hydrocephalus, made by clinical and CT or MRI imaging demonstrating ventricular dilation, and confirmed by an established protocol of continuous CSF drainage via spinal catheter. Patients who are found to be eligible for VP shunt insertion on the basis of improvement in cognition/psychomotor speed, gait, or urinary continence are referred for surgery

Exclusion Criteria:

Known peripheral gland failure (primary hypogonadism, primary adrenal insufficiency, primary hypothyroidism); known history of pituitary tumor, pituitary surgery, pituitary hemorrhage, brain irradiation, or of identified causes of secondary hydrocephalus (subarachnoidal bleeding, meningitis, encephalitis, head trauma).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00149721

United States, Maryland
GCRC Johns Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Eli Lilly and Company
Principal Investigator: Roberto Salvatori, MD Johns Hopkins University
  More Information Identifier: NCT00149721     History of Changes
Other Study ID Numbers: B9R-US-X041 (terminated)
Study First Received: September 7, 2005
Last Updated: March 1, 2010

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
pituitary function

Additional relevant MeSH terms:
Pituitary Diseases
Hydrocephalus, Normal Pressure
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 21, 2017